Research programme: heat shock protein-viral antigen fusions - Akela PharmaAlternative Names: Hsp 6/11
Latest Information Update: 18 Mar 2013
At a glance
- Originator Nventa Biopharmaceuticals Corporation
- Developer Akela Pharma
- Class Antigens; Heat shock proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Human papillomavirus infections